Evome Medical Technologies Inc. (EVMT.V)
| Previous Close | 0.1200 |
| Open | 0.1150 |
| Bid | 0.1100 x N/A |
| Ask | 0.1250 x N/A |
| Day's Range | 0.1100 - 0.1200 |
| 52 Week Range | 0.0800 - 0.3000 |
| Volume | |
| Avg. Volume | 76,528 |
| Market Cap | 9.925M |
| Beta (5Y Monthly) | 1.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2400 |
| Earnings Date | Nov 12, 2024 - Nov 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | May 24, 2017 |
| 1y Target Est | N/A |
- GlobeNewswire
Evome Medical Technologies Reviews Highlights of Low-CapEx Revenue Growth Plan
Posts updated corporate presentation to website Reminder: Conference call to be held on August 19th to discuss Q2 2024 financial results SHIRLEY, N.Y., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) highlights its low-CapEx plan for growing revenue in an updated corporate presentation now available at www.evomemedical.com/investor. The presentation, to be used during investor meetings planned for next month in New York, Vancouver, Montre
- GlobeNewswire
Evome Medical Technologies Reports Second Quarter 2024 Financial Results
Stabilizes business with a return to positive Adjusted EBITDAPromotes Gordon Bean to Chief Financial OfficerAnnounces August 19th conference call to discuss financial results SHIRLEY, N.Y., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) today reported financial results for the second quarter ended June 30, 2024, featuring $421,000 in positive Adjusted EBITDA1, a reduction in debt, financial performance momentum and significant progress
